Relatlimab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | LAG3 |
Clinical data | |
Other names | BMS-986016 |
ATC code |
|
Identifiers | |
CAS Number |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6472H9922N1710O2024S38 |
Molar mass | 145288.79 g·mol−1 |
Relatlimab (INN; development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma.[1][2]
This drug is being developed by Bristol-Myers Squibb. As of 2018, relatlimab is undergoing Phase II/III trials.[3]
References[]
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab, American Medical Association.
- ^ World Health Organization (2018). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119" (PDF). WHO Drug Information. 32 (2).
- ^ Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibody stubs
- Clinical trials sponsored by Bristol-Myers Squibb
- Monoclonal antibodies